The global oral transmucosal drugs market size was estimated to be USD 16.24 billion in 2023 and is expected to reach USD 35.65 billion by 2034 with a CAGR of 7.41% during the forecast period 2024-2034. The rising prevalence of chronic diseases, advantages of oral transmucosal drugs, growing focus on patient-centric care, and advancements in drug formulations will drive the market growth.
The medication delivery technologies and formulations that are being developed are continuously changing the market. The effectiveness and attractiveness of oral transmucosal medications are being further enhanced by the development of new materials including dissolvable films and mucoadhesive gels, which allow for more targeted and controlled drug release. For instance, Indivior PLC expanded access to medication-assisted therapy for opioid dependency in June 2023 when it introduced Suboxone Film (buprenorphine) in Australia.
By product type, the tablets segment accounted for the highest revenue-grossing segment in the global oral transmucosal drugs market in 2023 owing to the widespread familiarity and consumer preference for this traditional oral dosage form. Additionally, advancements in tablet formulations, such as rapid dissolving or effervescent tablets, have enhanced patient convenience and contributed to the segment's continued dominance in the market. Additionally, the buccal films segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on patient-friendly drug delivery systems, as buccal films offer advantages such as rapid drug absorption, improved bioavailability, and ease of administration.
By route of administration, the sublingual mucosa segment accounted for the highest revenue-grossing segment in the global oral transmucosal drugs market in 2023 owing to the rich vascular network beneath the tongue, facilitating rapid drug absorption and the onset of action. For instance, Novartis AG received FDA clearance in December 2023 to use Rizatriptan ODT (rizatriptan orally disintegrating tablets) as a therapy for acute migraines. Additionally, the buccal mucosa segment is predicted to grow at the fastest CAGR during the forecast period owing to the enhanced permeability, vascularization, and potential for sustained drug release associated with the buccal mucosa.
By indication, the neurological disorders segment accounted for the highest revenue-grossing segment in the global oral transmucosal drugs market in 2023 owing to the growing prevalence of neurological conditions, such as epilepsy, migraine, and anxiety disorders, which necessitate effective and rapid drug delivery. For instance, Pfizer Inc. said in November 2023 that it would invest $500 million in a new plant to manufacture oral transmucosal films for a range of uses. Additionally, the opioid dependence segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating global concerns surrounding opioid addiction and the increasing adoption of oral transmucosal drugs for opioid replacement therapy.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global oral transmucosal drugs market in 2023 owing to the widespread accessibility of these pharmacies, ensuring convenient and direct access for patients to purchase oral transmucosal medications. For instance, in December 2023, Eli Lilly and Company partnered with Vectura Group plc to develop inhaled and buccal film formulations for pain management and diabetic medications. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for digital healthcare solutions, the convenience of online purchasing, and the expanding adoption of e-commerce platforms for pharmaceutical transactions.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increasing prevalence of chronic diseases, and a high level of awareness and acceptance of oral transmucosal drug delivery systems among both healthcare professionals and patients. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of chronic diseases, a rising geriatric population, and the expanding healthcare infrastructure across countries in the region. For instance, GlaxoSmithKline plc (GSK): Launched Blenoxane (bleomycin) buccal tablets for localized head and neck cancer therapy in the US in September 2023.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
The medication delivery technologies and formulations that are being developed are continuously changing the market. The effectiveness and attractiveness of oral transmucosal medications are being further enhanced by the development of new materials including dissolvable films and mucoadhesive gels, which allow for more targeted and controlled drug release. For instance, Indivior PLC expanded access to medication-assisted therapy for opioid dependency in June 2023 when it introduced Suboxone Film (buprenorphine) in Australia.
By product type, the tablets segment accounted for the highest revenue-grossing segment in the global oral transmucosal drugs market in 2023 owing to the widespread familiarity and consumer preference for this traditional oral dosage form. Additionally, advancements in tablet formulations, such as rapid dissolving or effervescent tablets, have enhanced patient convenience and contributed to the segment's continued dominance in the market. Additionally, the buccal films segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing emphasis on patient-friendly drug delivery systems, as buccal films offer advantages such as rapid drug absorption, improved bioavailability, and ease of administration.
By route of administration, the sublingual mucosa segment accounted for the highest revenue-grossing segment in the global oral transmucosal drugs market in 2023 owing to the rich vascular network beneath the tongue, facilitating rapid drug absorption and the onset of action. For instance, Novartis AG received FDA clearance in December 2023 to use Rizatriptan ODT (rizatriptan orally disintegrating tablets) as a therapy for acute migraines. Additionally, the buccal mucosa segment is predicted to grow at the fastest CAGR during the forecast period owing to the enhanced permeability, vascularization, and potential for sustained drug release associated with the buccal mucosa.
By indication, the neurological disorders segment accounted for the highest revenue-grossing segment in the global oral transmucosal drugs market in 2023 owing to the growing prevalence of neurological conditions, such as epilepsy, migraine, and anxiety disorders, which necessitate effective and rapid drug delivery. For instance, Pfizer Inc. said in November 2023 that it would invest $500 million in a new plant to manufacture oral transmucosal films for a range of uses. Additionally, the opioid dependence segment is predicted to grow at the fastest CAGR during the forecast period owing to the escalating global concerns surrounding opioid addiction and the increasing adoption of oral transmucosal drugs for opioid replacement therapy.
By distribution channel, the retail pharmacies segment accounted for the highest revenue-grossing segment in the global oral transmucosal drugs market in 2023 owing to the widespread accessibility of these pharmacies, ensuring convenient and direct access for patients to purchase oral transmucosal medications. For instance, in December 2023, Eli Lilly and Company partnered with Vectura Group plc to develop inhaled and buccal film formulations for pain management and diabetic medications. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing preference for digital healthcare solutions, the convenience of online purchasing, and the expanding adoption of e-commerce platforms for pharmaceutical transactions.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, increasing prevalence of chronic diseases, and a high level of awareness and acceptance of oral transmucosal drug delivery systems among both healthcare professionals and patients. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of chronic diseases, a rising geriatric population, and the expanding healthcare infrastructure across countries in the region. For instance, GlaxoSmithKline plc (GSK): Launched Blenoxane (bleomycin) buccal tablets for localized head and neck cancer therapy in the US in September 2023.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product Type, Route of Administration, Indication, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Oral Transmucosal Drugs Market Report 2023 - 2034
Oral Transmucosal Drugs Market Analysis & Forecast by Product Type 2023 - 2034 (Revenue USD Bn)
- Tablets
- Films
- Liquid & Spray
- Others
Oral Transmucosal Drugs Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Sublingual Mucosa
- Buccal Mucosa
- Others
Oral Transmucosal Drugs Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Opioid Dependence
- Nausea and Vomiting
- Erectile Dysfunction
- Neurological Disorders
- Others
Oral Transmucosal Drugs Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Oral Transmucosal Drugs Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Oral Transmucosal Drugs Market: Product Type Estimates & Trend Analysis
8. Oral Transmucosal Drugs Market: Route of Administration Estimates & Trend Analysis
9. Oral Transmucosal Drugs Market: Indication Estimates & Trend Analysis
10. Oral Transmucosal Drugs Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Oral Transmucosal Drugs Market
13. Europe Global Oral Transmucosal Drugs Market
14. Asia Pacific Global Oral Transmucosal Drugs Market
15. Latin America Global Oral Transmucosal Drugs Market
16. MEA Global Oral Transmucosal Drugs Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Indivior PLC
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
- Mylan N.V.
- Eli Lilly and Company
- GlaxoSmithKline plc (GSK)
- Cipla Limited
- Teva Pharmaceutical Industries Ltd.
- Mundipharma International Limited
- Becton
- Dickinson and Company
- Insys Therapeutics Inc.
- Midatech Pharma PLC
- Galena Biopharma Inc.
- Cipher Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 16.24 Billion |
| Forecasted Market Value ( USD | $ 35.65 Billion |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
